EAM Investors’s Esperion Therapeutics ESPR Stock Holding History

EAM Investors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-65,683	Closed	-$4.75M	–	309
2018 Q1	$4.75M	Buy	65,683 +3,511	+6%	+$258K	0.79%	5
2017 Q4	$4.09M	Sell	62,172 -30,727	-33%	-$1.65M	0.73%	11
2017 Q3	$4.66M	Sell	92,899 -7,271	-7%	-$351K	0.62%	36
2017 Q2	$4.64M	Sell	100,170 -28,130	-22%	-$1.03M	0.77%	11
2017 Q1	$4.53M	Buy	+128,300	New	+$2.94M	0.71%	12
2015 Q2	–	Sell	-89,335	Closed	-$8.27M	–	335
2015 Q1	$8.27M	Sell	89,335 -94,685	-51%	-$6.11M	0.96%	1
2014 Q4	$7.44M	Buy	184,020 +115,099	+167%	+$3.52M	1.04%	1
2014 Q3	$1.69M	Buy	+68,921	New	+$1.1M	0.34%	98

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return

PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return